CTLA‐4‐Ig, a widely used biologic DMARD that operates by competitively inhibiting the CD28‐CD80/86 co‐stimulatory pathway, has been shown to have potential for preventing arthritis in clinical trials.34, 36. Here, CD80 is linked to arthritic joint disease.